BackMerckInc Overview
Merck & Co Inc

MerckInc Target Price

Analysts' average 12-month price target for MerckInc is $140.

Get informed when a big investor buys or sells

+ Follow

Share Price

$135.18

Average Target Price

$137.691.9% upside

13 analysts in the last 4 months

High: $155 | Low: $105

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Daiwa$1435.8% upsideOpen
2026-08-11Argus ResearchJasper Hellweg$1457.3% upsideOpen
2026-08-05Morgan StanleyTerence Flynn$11614.2% downsideOpen
2026-08-05GuggenheimVamil Divan$1468% upsideOpen
2026-07-29BarclaysEmily Field$15011% upsideOpen
2026-07-27BernsteinCourtney Breen$10522.3% downsideOpen
2026-07-13BMO Capital$1425% upsideOpen
2026-07-13GuggenheimVamil Divan$1457.3% upsideOpen
2026-07-06HSBCRajesh Kumar$15011% upsideOpen
2026-06-30Jefferies$1414.3% upsideOpen
2026-06-29Scotiabank$15514.7% upsideOpen
2026-06-02GuggenheimVamil Divan$1403.6% upsideOpen
2026-05-01Morgan StanleyTerence Flynn$11217.1% downsideOpen
2026-03-12Wells FargoMohit Bansal$15011% upsideOpen
2026-02-24RBC CapitalTrung Huynh$1425% upsideOpen
2026-02-13Deutsche BankJames Shin$15011% upsideOpen
2026-02-04Goldman SachsAsad Haider$1331.6% downsideOpen
2026-02-04BMO Capital$1350.1% downsideOpen
2026-02-04Bernstein$10026% downsideOpen
2026-02-03Scotiabank$1360.6% upsideOpen
2026-01-27Cantor Fitzgerald$11614.2% downsideOpen
2026-01-08Wolfe Research$1350.1% downsideOpen
2026-01-07UBS$1303.8% downsideOpen
2025-12-18BMO Capital$1303.8% downsideOpen
2025-12-12Morgan Stanley$10224.5% downsideOpen
2025-12-10HSBCRajesh Kumar$12011.2% downsideOpen
2025-12-05Guggenheim$1229.7% downsideOpen
2025-12-04ScotiabankLouise Chen$12011.2% downsideOpen
2025-12-02Goldman SachsAsad Haider$12011.2% downsideOpen
2025-11-03Morgan StanleyTerence Flynn$10026% downsideOpen
2025-09-17Berenberg BankLuisa Hector$9033.4% downsideOpen
2025-07-10Morgan StanleyTerence Flynn$9827.5% downsideOpen
2025-04-25BMO CapitalEvan Seigerman$8239.3% downsideOpen
2025-02-05Morgan StanleyTerence Flynn$10621.6% downsideOpen
2024-12-02BernsteinCourtney Breen$11018.6% downsideOpen
2024-11-15JefferiesAkash Tewari$1489.5% upsideOpen
2024-11-01BMO CapitalEvan David Seigerman$1360.6% upsideOpen
2024-10-09UBSTrung Huynh$1360.6% upsideOpen
2024-10-07BarclaysCarter Gould$1403.6% upsideOpen
2024-08-15JefferiesAkash Tewari$1478.7% upsideOpen
2024-07-31UBSColin Bristow$1425% upsideOpen
2024-07-31Bank of America SecuritiesGeoff Meacham$1457.3% upsideOpen
2024-06-12Wells FargoMohit Bansal$1403.6% upsideOpen
2024-05-30BMO CapitalEvan David Seigerman$1489.5% upsideOpen
2024-03-27Truist Financial$1425% upsideOpen
2024-03-27JefferiesAkash Tewari$1457.3% upsideOpen
2024-03-27Wells FargoMohit Bansal$1350.1% downsideOpen
2023-11-22Loop Capital MarketsEvan David Seigerman$1322.4% downsideOpen
2023-04-12OppenheimerJay Olson$1478.7% upsideOpen
2023-02-03Wells Fargo$12011.2% downsideOpen

MerckInc (MRK) FAQ

MerckInc posts a target price of $140. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $140 for MRK means covering analysts, on average, see the stock 1.9% upside of $135.18 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for MRK's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; MerckInc's other metric pages and overview cover the third.

Judging MerckInc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $140 here, then scan peer and history charts to see if the gap is persistent.